Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
|Videos|February 9, 2015
How Will Biosimilars Impact the US?
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.
Advertisement
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.
Advertisement
Related to this article
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
3
Cystatin C and the Future of Kidney Function Assessment
4
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
5